Epstein Secrets

0 0.34000 003971 36 100 Comemn isorrom 50=0 0.51000 002978 27 50 HO Rae Comma &moots 506298 5,027927 5253 907 ZOtSonte Wcieltal SOX Comecon ovum 705.737 1400500 5080031 SI 706 Comermcopoun - 000550 4102000 0 Commmoptions 1491.705 003000 040913 105 3.492 Commco <soon. 251

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

0 0.34000 003971 36 100 Comemn isorrom 50=0 0.51000 002978 27 50 HO Rae Comma &moots 506298 5,027927 5253 907 ZOtSonte Wcieltal SOX Comecon ovum 705.737 1400500 5080031 SI 706 Comermcopoun - 000550 4102000 0 Commmoptions 1491.705 003000 040913 105 3.492 Commco <soon. 251

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

0 0.34000 003971 36 100 Comemn isorrom 50=0 0.51000 002978 27 50 HO Rae Comma &moots 506298 5,027927 5253 907 ZOtSonte Wcieltal SOX Comecon ovum 705.737 1400500 5080031 SI 706 Comermcopoun - 000550 4102000 0 Commmoptions 1491.705 003000 040913 105 3.492 Commco <soon. 251

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th